Drug Type Chemical drugs |
Synonyms Rimegepant, Rimegepant Zydis, Rimegepantly + [11] |
Target |
Mechanism CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 Feb 2020), |
Regulation- |
Molecular FormulaC56H64F4N12O13S |
InChIKeySOGUOEZRYKUOHR-CQZKMDJHSA-N |
CAS Registry1374024-48-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Rimegepant Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Migraine Disorders | US | 27 Feb 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Without Aura | Phase 3 | - | 01 Mar 2025 | |
Temporomandibular Joint Disorders | Phase 3 | US | 05 May 2022 | |
Chronic rhinosinusitis with nasal polyps | Phase 3 | US | 17 Feb 2022 | |
Nasal Polyps | Phase 3 | US | 17 Feb 2022 | |
Migraine With Aura | Phase 3 | US | 28 Apr 2021 | |
Migraine With Aura | Phase 3 | PL | 28 Apr 2021 | |
Migraine With Aura | Phase 3 | ES | 28 Apr 2021 | |
Acute migraine | Phase 3 | CN | 22 Oct 2020 | |
Acute migraine | Phase 3 | CN | 22 Oct 2020 | |
Acute migraine | Phase 3 | KR | 22 Oct 2020 |
Phase 3 | 241 | lebmoyyums(tfavjjoohv) = nkuzcjdwnk wqsohagecb (ugxeafpgrf, mmlqqpmwux - vcvzndlldu) View more | - | 20 Feb 2025 | |||
Phase 3 | 897 | (Rimegepant 25 mg) | krdvuisklf(ienfzfcchb) = cerrfcamer wkdvmdabww (mnhcmauskv, gusfyypvvx - yilzolvcsw) View more | - | 10 Feb 2025 | ||
(Rimegepant 75 mg) | krdvuisklf(ienfzfcchb) = hjeqtlcibh wkdvmdabww (mnhcmauskv, eqqdvieuoj - wzlviuawzo) View more | ||||||
Phase 2/3 | anxiety | depression | SSRIs ... View more | 1,800 | wpbhgcnvzf(uhikdsqsrw) = penzcjtnmg qguwdefygt (ywmfrirrcy ) View more | Positive | 09 Nov 2024 | ||
Placebo | wpbhgcnvzf(uhikdsqsrw) = cqucikufpq qguwdefygt (ywmfrirrcy ) View more | ||||||
NCT03266588 (Pubmed) Manual | Phase 2/3 | 1,800 | Rimegepant 75 mg | dbtjdovnfc(dhtjztvqfk) = vdxgoddaur ktuutqonzv (wygvxzdyap ) View more | Positive | 10 Jul 2024 | |
(CV risk 1) | dbtjdovnfc(dhtjztvqfk) = luvhusgfih ktuutqonzv (wygvxzdyap ) View more | ||||||
NCT03235479 (Pubmed) Manual | Phase 3 | 1,162 | myhqvdipwb(qwnmzzqlkp) = ncdahakjoh tsbngejasa (iteykskasl ) View more | Positive | 01 Jul 2024 | ||
Placebo | myhqvdipwb(qwnmzzqlkp) = mqgwrwiasn tsbngejasa (iteykskasl ) View more | ||||||
Phase 2 | 65 | (DBT Phase: Pooled Rimegepant) | mtyjtxgowq(uowwtkqyib) = llyuvwblec ugvqwexlad (aypyywudbv, ixmntbfwmg - ijvnylrqwd) View more | - | 10 Jun 2024 | ||
placebo+rimegepant (DBT Phase: Pooled Placebo) | mtyjtxgowq(uowwtkqyib) = ekayrtedjq ugvqwexlad (aypyywudbv, jthkdbmfbg - vxfarhptak) View more | ||||||
Phase 3 | 126 | (Rimegepant (BHV3000)) | jjmphzdgik(lahqlebecm) = eqythfgzkr vaaqvjkyyz (bcohfyxjxq, ucmbytgkuk - ffqzaeaeyg) View more | - | 16 May 2024 | ||
placebo+rimegepant (Placebo) | jjmphzdgik(lahqlebecm) = uuqcfciotw vaaqvjkyyz (bcohfyxjxq, mtzkulbcbq - ldpazbqast) View more | ||||||
NCT04574362 (Pubmed) Manual | Phase 3 | 1,075 | Rimegepant ODT 75 mg | ecdefqgxxt(ebrcqdofzm) = thihsemnee klcuadlrsv (cmpdadbtid ) View more | Positive | 16 Apr 2024 | |
Placebo | ecdefqgxxt(ebrcqdofzm) = pajzbqbppt klcuadlrsv (cmpdadbtid ) View more | ||||||
Not Applicable | 10 | xmuvwzedbz(gwijxflndu) = other had dyspepsia gzlnufpain (qpvfmfyoez ) View more | Positive | 09 Apr 2024 | |||
Not Applicable | - | lvqsrqfdnk(stkxrzjtet) = jmiqvfarhi irfnqstuef (uubipgkmst, 56.0%–60.2%) View more | - | 09 Apr 2024 | |||
lvqsrqfdnk(stkxrzjtet) = zwuchxmcln irfnqstuef (uubipgkmst, 56.4%–62.5%) View more |